DocDollars

Verastem, Inc.

MA · United States · Reporting entity ID 100000461814

Total reported 2019–2025
$8.19M
#554 of 2,960 reporting companies — 0% of all reported industry payments
$1.71M in general payments across 3,704 records, plus $6.48M in research funding across 1,843 records.

How it breaks down

General payments $1,707,940
Research funding $6,482,685

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Verastem, Inc. reported $8.19M to US doctors and teaching hospitals from 2019 to 2025, ranking #554 of 2,960 reporting companies. 79% of that was research funding and 21% general payments such as consulting, speaking, food and travel. 3,704 general payment records and 1,843 research records were filed.

Common questions about Verastem, Inc.

How much has Verastem, Inc. paid US doctors?

Verastem, Inc. reported $8,190,625 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,707,940 in general payments, $6,482,685 in research funding.

How does Verastem, Inc. rank among drug and device companies?

It ranks #554 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Verastem, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.